Inadequate hepatitis B vaccination of adolescents and adults at an urban community health center

J Natl Med Assoc. 1997 Feb;89(2):86-92.


Hepatitis B remains a major public health problem in the United States, but public vaccination policy has targeted infants rather than the high-risk adults who constitute the vast majority of patients at imminent risk of infection. The effects of this policy were studied at a community health center in Boston. Adolescents and adults who attended a community health center between January 1, 1992 and May 31, 1993 and had human immunodeficiency virus (HIV) or another sexually transmitted disease (STD)--indications for vaccination according to the Centers for Disease Control and Prevention--were identified through chart review. The vaccination rate and missed opportunities were determined. In addition, directors of Boston health centers were surveyed on hepatitis B vaccine at their clinics. Of 178 individuals with HIV or another STD and without serologic evidence of prior exposure to hepatitis B, two (1.1%) received the vaccine. There were 342 missed opportunities. Only two of 14 medical directors said their clinics routinely offered vaccine to individuals with STDs. The medical directors rated financial barriers as more important obstacles to hepatitis B vaccination than nonfinancial barriers. These results indicate that many high-risk adolescents and adults do not receive a preventive intervention that is federally recommended, potentially life saving, and cost effective. Inadequate public funding for vaccine may be a key barrier for this population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Boston / epidemiology
  • Community Health Centers
  • Female
  • HIV Infections / epidemiology
  • Hepatitis B / epidemiology
  • Hepatitis B / prevention & control*
  • Hepatitis B Vaccines*
  • Humans
  • Male
  • Risk Factors
  • Sexually Transmitted Diseases / epidemiology
  • Urban Health Services
  • Vaccination / statistics & numerical data*


  • Hepatitis B Vaccines